

XerthraTM

High performance separation device
for blood derived products




Advanced
medical
devices

implai.com

The effect of the therapy based on platelet concentrate

Clinical efficacy of the therapy is determined by the abundance of anabolic factors, such as growth factors, whose number is directly proportional to the concentration of the platelets in the injectable product¹.



The growth factors and cytokines are a source of an appropriate cellular response, initiating regeneration processes².

Xerthra™ separation device



Xerthra™ is a highly efficient separation device, which due to its unique design and construction allows efficient separation and isolation of a very high number of cells (e.g. platelets) and proteins (e.g. growth factors) in the final injectable product. Thus, the use of Xerthra™ ensures clinical functionality of the final injectable, blood-derived product obtained with the device³.

Superiority of Xerthra™ separation device made from Makrolon® polycarbonate

Xerthra™

Makrolon® due to very low surface energy, ensures low binding affinity of proteins and cells by Xerthra™ separation device.


Xerthra™ separation device provides maximum platelets and growth factors recovery rate⁵.



Tube-based kits

Simple, tube-based separation devices are made of material with high surface energy, thus they actively bind proteins, cells and growth factors on their surface⁶. This leads to substantial loss of functional factors in the final product and subsequent loss of a therapeutic functionality of the treatment.

Unique functional features of Xerthra™ separation device




Semi-closed system

Xerthra™ pressure equalization system gives the possibility to transfer the blood into the separation device without necessity for removal of the stopper. This significantly increases the safety of the entire procedure.

Ensured stabilization

The transverse rings used in Xerthra™ separation device ensure better stability and balance during centrifugation. This translates into a better mass distribution, what improves blood separation and protects the biological material i.a. from hemolysis.



Precise process



Additional markings allow for precise collection of a required volume of platelet-rich product - 3 ml, 2 ml or 1 ml.



The separation device can be accurately filled with blood up to the 15 ml level. The transparency of Xerthra™ ensures precise phase observation after separation.

Highly efficient Xerthra™ separation device is available in various options for preparation of different platelet-rich products

Provides injectable product enriched with platelets, growth factors and cytokines, inducing pro-anabolic driving force of tissue regeneration⁹.


Xerthra™ separation device in different variants allows to obtain a various blood-derived products.




Xerthra™ provides a safe and clinically functional platelet-enriched product


Autologous blood-derived product obtained by Xerthra™ is not only therapeutically functional due to increased abundance of platelets (PLTs) and white blood cells (WBCs), but it's also safe due to significant reduction of red blood cells (RBCs) within⁸.

 up to 9.7-times PLTs

 2.2-times WBCs




Xerthra™ separation device allows to obtain autologous product characterized by the platelet count above the therapeutic threshold of **1,000,000 PLT/ μ L**, with **5-times more concentrated product** compared to tube-based kits⁵.



Xerthra™ PRP kit

Xerthra PRP™ kit allows to obtain a therapeutically functional autologous product enriched with platelets and leukocytes.




Xerthra™ PRP PURE kit

Xerthra™ PRP PURE kit allows to obtain a therapeutically functional autologous product enriched with platelets and simultaneously decreased amount of leukocytes.



Xerthra™ iPRF kit

Xerthra™ iPRF kit allows to obtain injectable platelet-rich fibrin, which is a platelet concentrate with a unique ability for fibrin network creation.





Advanced medical devices

Global marketing

Implai Sp. z o.o.

Hutnicza 15 B

81-061 Gdynia, Poland, EU

☎ +48 58 727 06 06

✉ office@implai.com

Legal manufacturer

Biovico Sp. z o.o.

Hutnicza 15 B

81-061 Gdynia, Poland, EU

☎ +48 58 660 44 88

✉ office@biovico.com



implai.com



biovico.com



[references](#)